重组人血小板生成素治疗慢性难治性免疫性血小板减少性紫癜的临床价值  

Clinical Value of Recombinant Human Thrombopoietin in the Treatment of Chronic Refractory Immune Thrombocytopenic Purpura

作　　者：刘杨 

机构地区：[1]吉林省辽源矿业集团职工总医院血液科

出　　处：《中国卫生标准管理》2018年第4期67-68,共2页China Health Standard Management

摘　　要：目的分析重组人血小板生成素治疗慢性难治性免疫性血小板减少性紫癜的临床价值。方法选取我院2015年2月—2017年2月收治的34例慢性难治性免疫性血小板减少性紫癜患者,给予所有患者重组人血小板生成素治疗,治疗14 d后观察临床治疗效果。结果患者治疗后的血小板计数高于治疗前,差异具有统计学意义(P<0.05)。用药后患者的临床有效率高达94.12%,不良反应发生率仅为5.89%。结论重组人血小板生成素用于慢性难治性免疫性血小板减少性紫癜的治疗中,能够有效提高血小板计数,改善患者出血症状,临床应用安全有效。Objective To analyze the clinical value of recombinant human thrombopoietin in the treatment of chronic refractory immune thrombocytopenic purpura. Methods 34 cases of chronic refractory immune thrombocytopenic purpura patients in our hospital from February 2015 to February 2017 were treated with recombinant human thrombopoietin treatment, clinical curative effect after the treatment of 14 d was observed. Results The platelet count before treatment was significantly higher than that of the treatment, and the difference was statistically significant （P 〈 0.05）. The clinical effective rate of the patients was 94.12% and the incidence of adverse reaction was only 5.89%. Conclusion Recombinant human thrombopoietin in chronic refractory immune thrombocytopenic purpura treatment, can effectively improve the platelet count, improve bleeding symptoms, the clinical application is safe and effective.

关 键 词：重组人血小板生成素 慢性难治性免疫性血小板减少性紫癜 应用价值 

分 类 号：R978[医药卫生—药品]